Company profile

Exelixis, Inc.

Pipeline8 assets

ZanzalintinibXL092 / MET/VEGFR/AXL/MER / Next-generation TKI / Oncology
Colorectal cancerPivotal / Phase 3STELLAR-303: zanzalintinib + atezolizumab vs. regorafenibNon-clear cell renal cell carcinomaPivotal / Phase 3STELLAR-304: zanzalintinib + nivolumab vs. sunitinibNeuroendocrine tumorsPivotal / Phase 2/3STELLAR-311: zanzalintinib vs. everolimus
XL309XL309 / USP1 / USP1 inhibitor / Oncology
Multiple solid tumorsPhase 1XL309 or XL309 + olaparib
XB010XB010 / 5T4 / Next-generation 5T4-MMAE ADC / Oncology
Multiple solid tumorsPhase 1XB010 or XB010 + pembrolizumab
XB628XB628 / PD-L1 + NKG2A / Bispecific antibody / Oncology
Multiple solid tumorsPhase 1Ongoing clinical study
XB371XB371 / Tissue factor / Next-generation TF-TOPOi ADC / Oncology
Multiple solid tumorsPhase 1Ongoing clinical study
ADU-1805ADU-1805 / SIRPα / SIRPα-targeting mAb / Oncology
Multiple solid tumorsPhase 1ADU-1805 or ADU-1805 + pembrolizumab
XB773XB773 / DLL3 / DLL3-TOPOi ADC / Oncology
Not disclosedDiscovery/PreclinicalDiscovery/Preclinical
SSTR2 AgonistSomatostatin receptor subtype 2 / SSTR2 agonist program development candidate / Oncology
Not disclosedDiscovery/PreclinicalDiscovery/Preclinical

Latest news12 items

Jun 22, 2026

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

ALAMEDA, Calif. --(BUSINESS WIRE)--Jun. 22, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival ( OS) in the subset of patients without active liver metastases (non-liver metastases, NLM) in the phase 3 STELLAR-303

Trial Results • Phase 3STELLAR-303 NLM subgroup OS results Mon, Jun 22, 2026

May 30, 2026

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo – ALAMEDA, Calif. --(BUSINESS WIRE)--May 30, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced results from a

Presentation / Abstract • Phase 3ASCO presentation Fri, May 29, 2026

May 27, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in June: 2026 Jefferies Global Healthcare Conference:

May 21, 2026

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types

– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented – ALAMEDA, Calif. --(BUSINESS WIRE)--May 21, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced presentations for its flagship product, CABOMETYX ® (cabozantinib), and its

Presentation / Abstract • Phase 3ASCO oral presentation Fri, May 29, 2026, 2:45 PM CDT

May 19, 2026

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial – ALAMEDA, Calif. --(BUSINESS WIRE)--May 19, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that the company has entered into a

May 7, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in May: BofA Securities Health Care Conference 2026:

May 5, 2026

Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2027 - - Conference Call and Webcast Today

Apr 21, 2026

Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Apr. 21, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2026 financial results will be released on Tuesday, May 5, 2026 after the markets close. At 5:00 p.m.

Feb 24, 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March

- Presentations to be webcast on www.exelixis.com - ALAMEDA, Calif. --(BUSINESS WIRE)--Feb. 24, 2026-- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in March: TD Cowen 46 th Annual Health Care

Feb 10, 2026

Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

– Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 – – Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal Year 2025, including $547 million for the Fourth Quarter of 2025 – – GAAP Diluted EPS of

Feb 2, 2026

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

– The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 – – Application is based on results from the phase 3 STELLAR-303 pivotal trial, in which zanzalintinib in combination with atezolizumab improved median overall survival and significantly reduced the risk of

Jan 27, 2026

Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 27, 2026-- Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and fiscal year 2025 financial results will be released on Tuesday, February 10, 2026 after the markets